Targeting bacterial proteins to treat inflammatory bowel diseases
Targeting bacterial proteases involved in PAR signaling to treat inflammatory bowel diseases
This study is looking at how certain bacteria in the gut might affect inflammation and the protective barrier in people with inflammatory bowel diseases like Crohn's and ulcerative colitis, with the hope of finding new ways to help ease their symptoms.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project ID | NIH-10911223 on NIH RePORTER |
What this research studies
This research investigates the role of bacterial proteases in the signaling pathways that contribute to inflammatory bowel diseases (IBD) like Crohn's disease and ulcerative colitis. By understanding how these proteases affect the gut's barrier function and inflammation, the research aims to identify new therapeutic targets. Patients with IBD often experience debilitating symptoms, and this study seeks to explore innovative treatments that could alleviate these issues. The approach involves analyzing the interactions between bacterial proteins and the body's signaling mechanisms to develop potential new therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Crohn's disease or ulcerative colitis who are experiencing severe symptoms.
Not a fit: Patients with IBD who are in remission or those with other gastrointestinal disorders unrelated to protease activity may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly reduce the symptoms and improve the quality of life for patients with inflammatory bowel diseases.
How similar studies have performed: Previous research has shown promise in targeting protease signaling pathways for treating gastrointestinal diseases, indicating that this approach could be effective.
Where this research is happening
Stanford, United States
- Stanford University — Stanford, United States (Active)
Researchers
- Principal investigator: Bogyo, Matthew — Stanford University
- Study coordinator: Bogyo, Matthew
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.